Vagistat

Vagistat®

Tioconazole, see there.
References in periodicals archive ?
For instance, Bristol-Myers Squibb Co.'s Vagistat 1 and Johnson & Johnson's Monistat 1, two one-day yeast infection treatments that were given Food and Drug Administration approval for O-T-C sale in 1997, quickly became two of the best-selling feminine hygiene medicinal products on the market.
Top brands include Johnson & Johnson Co.'s Monistat, Bristol-Myers Squibb Co.'s Vagistat, Bayer Corp.'s Femstat and Mycelex, and Schering-Plough Corp.'s Lotrimin.
Leading brands in the category include Johnson & Johnson's Monistat, Bristol-Myers Squibb Co.'s Vagistat, Bayer Corp.'s Femstat and Mycelex, and Schering-Plough Corp.'s Gyne-Lotrimin.
Fleet 9.5% 53,889 22,968 Massengill GlaxoSmithKline 7.5% 42,518 17,802 Monistat 7 Ortho-McNeil 7.1% 40,452 3,605 Monistat 1 Ortho-McNeil 6.2% 35,308 2,369 Vagisil Combe 5.1% 29,131 6,635 Vagistat 1 Bristol-Myers Squibb 4.6% 25,941 2,047 K-Y Ortho-McNeil 4.1% 23,147 6,543 FDS Alberto-Culver 3.6% 20,134 6,299 Gyne-Lotrimin 3 Pfizer 2.9% 16,631 1,480 (*)Private label brands account for 18.4% of dollar sales and 22.3% of unit sales.
For instance, when Johnson & Johnson's (J&J's) Monistat 1 and Bristol-Myers Squibb Co.'s Vagistat 1, two one-day yeast-infection treatments, were given Food and Drug Administration approval for O-T-C marketing five years ago they quickly became two of the best-sellers in the feminine hygiene category.
Fleet 8.7% 36,318 15,050 Monistat 7 Ortho-McNeil 7.3% 30,653 2,602 Monistat Ortho-McNeil 6.4% 26,947 1,652 Massengill GlaxoSmithKline 5.3% 22,179 9,466 Vagisil Combe 5.1% 21,365 4,704 1 Day -- 4.8% 20,232 1,327 K-Y Ortho-McNeil 4.7% 19,505 5,195 Vagistat 1 Bristol-Myers Squibb 4.0% 16,873 1,274 FDS Alberto-Culver 3.0% 12,502 3,680 * Private label brands account for 15.5% of dollar sales and 19.4% of unit sales.
Besides Excedrin, brands Novartis will acquire from Bristol-Myers include Bufferin, a systemic analgesic; 4-Way, a nasal decongestant: and Vagistat, an antifungal.
Other strong sellers in the category include Vagistat, manufactured by Bristol-Meyers Squibb Co., and Replens, supplied by Lil' Drug Store Products Inc.
Besides Excedrin, other brands Novartis acquired from Bristol-Myers include Bufferin, a systemic analgesic; 4-Way, a nasal decongestant; and Vagistat, an antifungal.
Other brands included in the agreement are the Bufferin systemic analgesic, Keri skin care line, 4-Way nasal decongestant, Comtrex cold flu medicine, No-Doz alertness aid, Vagistat antifungal brand and Mineral Ice topical analgesic.
(+2.4%) Market Dollar sales Dollar sales LEADING BRANDS ** share (000) % change Monistat 1 23.1% $36,948 + 2.8% Monistat 3 15.6% 24,957 - 8.3% Monistat 7 9.7% 15,446 + 1.1% Monistat 1 Day 4.7% 7,552 + 1.5% Replens 3.4% 5,473 + 7.3% Vagistat 1 3.4% 5,360 + 3.0% Rephresh 2.4% 3,822 + 35.7% Summer's Eve 2.2% 3,467 + 36.8% Azo Yeast 1.8% 2,858 - 0.2% TOTAL UNIT SALES* 23.4 mil.